Scholars Central

Review articlePublished 27 Jul 2016

Management of transitional cell carcinoma by targeting the epidermal growth factor receptor

Authors: Nicholas R Brook, Alex J Colquhoun, J Kilian Mellon

Clinical Practice

Volume 3 · Issue 3 · Pages 407

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The epidermal growth factor receptor (EGFR) family and its ligands play a central role in the development and progression of urothelial transitional cell carcinoma. Alterations in receptor physiology are associated with propagation of malignancy, and overexpression is an adverse prognostic feature associated with decreased survival. Knowledge of abnormalities in EGFR physiology has been harnessed to explore potential avenues for treatment. Strategies for inhibition or abrogation of the EGFR signal in the setting of transitional cell carcinoma include the application of anti-EGFR antibodies and EGFR tyrosine kinase inhibitors as sole and salvage agents, and as adjuvant treatment with chemotherapy and radiation. These novel drugs may permit greater treatment efficacy, reduced toxicity and improved organ preservation in this common disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Nicholas R Brook”
  • BylineArticles whose byline prints “Alex J Colquhoun”
  • BylineArticles whose byline prints “J Kilian Mellon”